SphenoMed Intermountain

Distributor of the SphenoCath device.
Introducing the


A new and simple way to perform an old and difficult procedure. A Patented and registered FDA category-1 trans-nasal ENT drug delivery device which many practitioners over several years have found to be very effective in the treatment of:


  • 18% of women of child bearing age.
  • 150 million work days lost in America.
  • $10 billion in direct costs.

Cluster Headaches

  • Very responsive to SPG block.
  • So severe and refractory, they have earned the nickname “suicide headaches”.

Trigeminal Neuralgia

  • Often become a surgical problem if not treated with an effective therapy.

Post-Concussion Headache

  • Often problematic long after the original injury.

For over 100 years it has been known that correctly impacting the sphenopalatine ganglion and the trigeminal system often results in beneficial effects on several significant and often debilitating neurologic problems such as migraine, cluster headache, trigeminal neuralgia, etc.

Over the past several decades, the various techniques used to access this area have proven to be technically difficult, uncomfortable, and in some cases, quite dangerous. However, when an adequate amount of an appropriate medication is delivered to the target area, relief has been achieved in most cases.

The SphenoCath® is designed to enable quick, easy, and safe access to the Sphenoethmoidal recess in the posterior/superior aspect of the sinus passageway.

The use of this delivery device in trained hands requires very little time, whether being done as a simple office procedure by tactile feel, or in an interventional radiology suite under fluoroscopic guidance.

Delivery of medication to this target allows for simple diffusion through a thin mucosal layer to the location of neural structures known as the sphenopalatine ganglion and some of the proximal branches of the trigeminal system.

When done gently and correctly, this procedure is very well tolerated, and extremely safe. As mentioned earlier, and as has been shown for over a century, delivery of an appropriate medication to this target area has often provided immediate, and in most cases, long lasting benefit.

Formal and informal trials are underway investigating the use of this device in the treatment of post-concussion headache and in the treatment of acute opiate withdrawal symptoms. It is also being used by several practitioners for delivery of NAD+, stem cells, growth factors, and peptides.

Some clinicians report good response in PTSD patients as well.

Several forward-thinking clinicians and scientists have shown great interest in the potential uses of this simple, but unique delivery device.